Table 2.
Demographic characteristics of the participants in phase 2
|
3–5 years |
6–12 years |
13–17 years |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine 2 μg (n=60) | Vaccine 4 μg (n=60) | Vaccine 8 μg (n=60) | Control (n=60) | Vaccine 2 μg (n=60) | Vaccine 4 μg (n=60) | Vaccine 8 μg (n=60) | Control (n=60) | Vaccine 2 μg (n=60) | Vaccine 4 μg (n=60) | Vaccine 8 μg (n=60) | Control (n=60) | |
| Age, years | ||||||||||||
| Mean | 4·6 (0·8) | 4·6 (0·8) | 4·4 (0·8) | 4·7 (0·7) | 9·6 (2) | 9·6 (2·2) | 8·8 (2) | 9·9 (1·8) | 15 (1·2) | 14·9 (1·3) | 15 (1·4) | 14·9 (1·4) |
| Median | 4·8 (3·8–5·3;3·0–5·9) | 4·7 (3·9–5·3;3·1–5·9) | 4·4 (3·8–5·1;3·1–5·9) | 4·7 (4·1–5·3;3·2–5·9) | 10·2 (7·7–11·3;6·1–13·0) | 9·4 (7·9–11·5;6·2–13·0) | 8·3 (6·9–10·4;6·2–12·7) | 10·0 (8·6–11·7;6·5–12·9) | 14·7 (14·0–15·9;13·1–17·6) | 14·8 (13·8–15·9;13·0–18·0) | 14·7 (13·7–16·0;13·0–17·9) | 14·8 (13·6–15·7;13·0–18·0) |
| Sex | ||||||||||||
| Male | 31 (52%) | 32 (53%) | 25 (42%) | 31 (52%) | 31 (52%) | 33 (55%) | 32 (53%) | 26 (43%) | 30 (50%) | 32 (53%) | 39 (65%) | 32 (53%) |
| Female | 29 (48%) | 28 (47%) | 35 (58%) | 29 (48%) | 29 (48%) | 27 (45%) | 28 (47%) | 34 (57%) | 30 (50%) | 28 (47%) | 21 (35%) | 28 (47%) |
| Ethnicity | ||||||||||||
| Han | 59 (98%) | 57 (95%) | 60 (100%) | 59 (98%) | 58 (97%) | 56 (93%) | 59 (98%) | 57 (95%) | 60 (100%) | 60 (100%) | 60 (100%) | 60 (100%) |
| Hui | 1 (2%) | 3 (5%) | 0 | 1 (2%) | 2 (3%) | 4 (7%) | 1 (2%) | 3 (5%) | 0 | 0 | 0 | 0 |
Data mean (SD), median (IQR; range), or n (%).